The Inflamed Intestinal Barrier as a Formulation Variable in Oral Nanocarrier Design: Evidence-Informed Principles for Mucus Interaction, Epithelial Access, and Translational Testing
Open Access
- 9 September 2026
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1132
Abstract
Oral nanocarrier development for inflammatory bowel disease (IBD) is complicated by inflammation-dependent changes in mucus, epithelial integrity, and immune-cell interactions. This critical narrative review examines comparative evidence from in vitro systems, animal models, and human intestinal tissue, alongside clinical studies, to assess how barrier state modifies formulation performance. Across the reviewed studies, particle size alone does not consistently predict lesion accumulation, while surface chemistry, coating, geometry, and stability in gastrointestinal fluids influence mucus interaction, cellular access, and payload release. Tissue-associated fluorescence, increased permeability, and cellular uptake do not independently establish intact-carrier transport or productive delivery. Clinical trials of selected oral nano-enabled formulations report improvements in some disease outcomes but do not establish inflammation-selective delivery as the underlying mechanism. We propose an evidence-informed benchmarking framework linking characterization in biological media to mucus transport or retention, epithelial–immune responses, spatial localization, target engagement, and safety. Matched healthy and inflamed comparators are central to testing selectivity, and preclinical findings must be distinguished from clinical validation. Artificial intelligence may support barrier-state-aware formulation optimization but requires standardized datasets and prospective experimental validation. Given the heterogeneous evidence base and limited direct human delivery studies, prospective validation should prioritize local payload delivery and therapeutic benefit without exacerbating intestinal barrier injury.Keywords
Funding Information
- Medical University of Bialystok
This publication has 108 references indexed in Scilit:
- Evaluation of oral nano-curcumin formulation effectiveness in patients with mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind clinical trialNaunyn-Schmiedeberg's Archives of Pharmacology, 2025
- Tracking In Vivo Lipolysis of Lipid Nanocarriers Using NIR‐II Polarity‐Sensitive Fluorescent ProbesSmall Methods, 2025
- Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systemsDrug Delivery and Translational Research, 2024
- ROS-responsive nanoparticles targeting inflamed colon for synergistic therapy of inflammatory bowel disease via barrier repair and anti-inflammationNano Research, 2024
- Selective Uptake Into Inflamed Human Intestinal Tissue and Immune Cell Targeting by Wormlike Polymer MicellesSmall, 2023
- Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticlesMedicinal Research Reviews, 2020
- Nanocrystals: A perspective on translational research and clinical studiesBioengineering & Translational Medicine, 2018
- The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients’ self‐reported well‐being: A randomized double‐blind controlled trialJournal of Cellular Biochemistry, 2018
- Surface charge tunable nanoparticles for TNF-α siRNA oral delivery for treating ulcerative colitisNano Research, 2018
- The effect of saliva on the fate of nanoparticlesClinical Oral Investigations, 2017